Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study.
Deschasaux-Tanguy M, Szabo de Edelenyi F, Druesne-Pecollo N, Esseddik Y, Allègre J, Srour B, Galan P, Hercberg S, Severi G, Zins M, Wiernik E; SAPRIS-SERO study group; de Lamballerie X, Carrat F, Touvier M. Deschasaux-Tanguy M, et al. Sci Rep. 2023 Mar 23;13(1):4775. doi: 10.1038/s41598-023-30714-9. Sci Rep. 2023. PMID: 36959255 Free PMC article. Clinical Trial.
Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
Bani-Sadr F, Lapidus N, Bedossa P, De Boever CM, Perronne C, Halfon P, Pol S, Carrat F, Cacoub P; French National Agency for Research on AIDS; Viral Hepatitis-HC02-Ribavic Study Team. Bani-Sadr F, et al. Among authors: lapidus n. Clin Infect Dis. 2008 Mar 1;46(5):768-74. doi: 10.1086/527565. Clin Infect Dis. 2008. PMID: 18248298
Risk factors for bacterial infections in HIV/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.
Bani-Sadr F, Goderel I, Lapidus N, Driss H, Simon A, Rosenthal E, Morand P, Lunel-Fabiani F, Pol S, Cacoub P, Perronne C, Carrat F; ANRS HC02 - RIBAVIC Study Team. Bani-Sadr F, et al. Among authors: lapidus n. AIDS. 2008 Jul 11;22(11):1385-7. doi: 10.1097/QAD.0b013e328305bd8d. AIDS. 2008. PMID: 18580626 Free article. Clinical Trial. No abstract available.
Gamma glutamyl transferase elevation in HIV/Hepatitis C virus-coinfected patients during interferon-ribavirin combination therapy.
Bani-Sadr F, Lapidus N, Rosenthal E, Gerard L, Foltzer A, Perronne C, Cacoub P, Pol S, Carrat F; ANRS HC02-Ribavic Study Team. Bani-Sadr F, et al. Among authors: lapidus n. J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):429-30. doi: 10.1097/QAI.0b013e31819a2429. J Acquir Immune Defic Syndr. 2009. PMID: 19322037 Clinical Trial. No abstract available.
Signal detection on a patient cohort: A disproportionality analysis of the ANRS CO22 HEPATHER cohort to identify associations between direct acting antivirals and adverse events in patients with hepatitis C virus chronic infection.
Feldman SF, Lapidus N, Dorival C, Diallo A, Amri I, Fontaine H, Pol S, Carrat F; ANRS/AFEF HEPATHER study group. Feldman SF, et al. Among authors: lapidus n. Pharmacoepidemiol Drug Saf. 2018 Jul;27(7):797-805. doi: 10.1002/pds.4552. Epub 2018 May 11. Pharmacoepidemiol Drug Saf. 2018. PMID: 29749668
Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study.
Lam L, Fontaine H, Bourliere M, Lusivika-Nzinga C, Dorival C, Thabut D, Zoulim F, Habersetzer F, Asselah T, Duclos-Vallee JC, Bronowicki JP, Mathurin P, Decaens T, Ganne N, Guyader D, Leroy V, Rosa I, De Ledinghen V, Cales P, Causse X, Larrey D, Chazouilleres O, Gelu-Simeon M, Loustaud-Ratti V, Metivier S, Alric L, Riachi G, Gournay J, Minello A, Tran A, Geist C, Abergel A, Raffi F, D'Alteroche L, Portal I, Lapidus N, Pol S, Carrat F; ANRS/AFEF Hepather study group. Lam L, et al. Among authors: lapidus n. Clin Res Hepatol Gastroenterol. 2021 Sep;45(5):101713. doi: 10.1016/j.clinre.2021.101713. Epub 2021 Apr 27. Clin Res Hepatol Gastroenterol. 2021. PMID: 33930591 Free article.
Performance of algorithms for identifying patients with chronic hepatitis B or C infection in the french health insurance claims databases using the ANRS CO22 HEPATHER cohort.
Lam L, Fontaine H, Lapidus N, Bellet J, Lusivika-Nzinga C, Nicol J, Dorival C, Cagnot C, Hejblum G, Pol S, Bourlière M, Carrat F; ANRS/AFEF HEPATHER Study Group. Lam L, et al. Among authors: lapidus n. J Viral Hepat. 2023 Mar;30(3):232-241. doi: 10.1111/jvh.13788. Epub 2022 Dec 27. J Viral Hepat. 2023. PMID: 36529681
96 results